Leveraged Finance Industry to Gather at Sixth Annual Melanoma Benefit

Event Set for May 24 at New York City’s Rockefeller Center: The
Summer Garden

NEW YORK–(BUSINESS WIRE)–The leveraged finance community will gather for the sixth annual
Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party to
raise funds for the Melanoma Research Alliance (MRA), the largest
private funder of melanoma research. Melanoma is the deadliest form of
skin cancer, and MRA is dedicated to fighting, treating, and curing
melanoma.

The event will be held from 6:00-9:00 p.m. on Wednesday, May 24, at the
Summer Garden at Rockefeller Center. It will be chaired by Brendan
Dillon of UBS; Lee Grinberg of Elliott Management; George Mueller and
Cade Thompson of KKR; Jeff Rowbottom of PSP Investments; and Trevor Watt
of Hellman & Friedman.

LFFM is a premier gathering of professionals from the leveraged finance,
private equity, and investment communities who come together to fight
melanoma. Previous years’ events have featured some of the most
prominent names in the financial industry, including Carl Icahn, Michael
Milken, Leon Black, Henry Kravis and Howard Marks.

Over 1,000 leaders from throughout the industry, including dealmakers
from banks, investment firms, law firms, issuers and sponsors are
expected to attend.

Since the inaugural event in 2012, LFFM has raised over $6.8 million to
support MRA’s global research programs, working toward eliminating
suffering and death from melanoma. Tickets are $300 and may be purchased
by visiting www.curemelanoma.org/LFFM.

The event seeks to raise funds to advance research and educate attendees
on the dangers of melanoma and the importance of sun safety and early
detection. If melanoma is found early—before it has spread beyond the
skin—it is almost always treatable. Past events have led to attendees
scheduling skin checks and even to the discovery and treatment of
several early-stage melanomas.

Recent landmark advances in melanoma treatments have provided new
options for patients, and melanoma stands as the case study for
state-of-the-art cancer drug development, precision medicine and
immunotherapy. The data that melanoma scientists are generating is also
benefiting cancer researchers in many fields, including those studying
bladder, brain, breast, colon, kidney, leukemia, lymphoma, lung,
pancreatic, and prostate cancer.

Over 87,000 Americans are expected to be diagnosed with melanoma in
2017, and incidence of the disease continues to rise. Melanoma is one of
the most common cancers
in young adults
—especially young women. Thanks to research funded
by MRA, the treatment outlook for the disease has improved in recent
years, yet further advances are needed to fully eliminate suffering and
death related to melanoma.

About The Melanoma Research Alliance (MRA)

MRA is a public charity formed in 2007 under the auspices of the Milken
Institute, with the generous founding support of Debra and Leon Black.
MRA to date has dedicated more than $88 million to research seeking to
better prevent, diagnose, and treat melanoma. Due to the ongoing support
of its founders, 100% of every dollar MRA raises goes directly to
funding melanoma research. The organization is poised to build on recent
momentum in the field, accelerating the pace of scientific discovery and
translation in order to eliminate suffering and death due to melanoma.
MRA’s ability to fund wide-ranging research in melanoma is amplified by
unique multi-faceted collaborations with individuals, private
foundations and corporations.

For more information on MRA, visit www.CureMelanoma.org.

Contacts

Melanoma Research Alliance
Pamela Goldsmith, 202-336-8922
pgoldsmith@curemelanoma.org
or
Anreder
& Company
Steven S. Anreder / Michael Wichman, 212-532-3232
steven.anreder@anreder.com
michael.wichman@anreder.com